A Phase 3 interventional study of Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A) and Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B) in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 10 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.
Among the 40 studies testing beclomethasone in Asthma, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 20 in phase 3, and was the 38th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 22 · Phase 4 9
First in 1995; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is close to the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 67 across the 40 interventional studies. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 40 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
81 studies in Asthma by Chiesi Farmaceutici S.p.A.: 11 open now, 11 under way, 2 of them phase 3. Of 69 finished, 13 (19%) have results posted.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 35th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2022, is one of 24 in phase 3, and was the 58th registered.
Chiesi Farmaceutici S.p.A.’s Asthma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing beclomethasone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 81 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study assessed the influence of pink vs. white pressurized metered-dose inhaler (pMDI) actuators on asthma symptoms perception. There was no prespecified primary objective. The following objectives were assessed:
For both treatment periods, "baseline" for the questionnaire data was the 14-day period prior to the first treatment period, and for AQLQ was the value recorded at Visit 2.
This was a phase IIIb, exploratory, double-blind, randomised, multicentre, psychopharmacological, 2x2 cross-over study in adult subjects with moderate to severe asthma.
A total of 78 randomised subjects in 10 actives centres were involved. The study focused on the psychopharmacological aspects, particularly on the subjects' preference for the device and on the impact of the device's features on subjects' perception of asthma symptoms. Subjects were informed that the study treatments were the same medication they had received before enrolment as maintenance therapy (i.e. Foster® 100/6 µg pMDI), but with differing device characteristics.
The study lasted approximately 6 weeks for each subject and comprised four visits (Visit [V] 1 to V4), including:
After signing the ICF, subjects were screened at the investigational site during the screening/randomisation visit (V1). On the same day, and after checking all inclusion and exclusion criteria, eligible subjects were randomised to one of two study treatment sequences and followed the study treatment sequence as follows:
From V2 (Day 15), subjects were instructed to take CHF1535 100/6 µg pMDI via Inhaler A and Inhaler B during two consecutive periods of 14 days each (first and second treatment periods) in a sequential way dictated by the randomisation:
The first treatment period started at V2 (Day 15) and the second treatment period started at V3 (Day 29), with the end of study visit taking place at V4 (Day 43). A window of ±1 day was allowed for the dates of all study visits except V1 (Day 1).
Please note that "Change from baseline in average VAS score perceptions of asthma-over the 14 Days of treatment - Question #3" was reported as PRIMARY ENDPOINT to comply with CT.gov register requirements, but it should be considered as an OTHER PRE-SPECIFIED endpoint like the other endpoint listed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group first received Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg pressurized metered-dose inhaler (CHF1535 100/6 µg pMDI) using Inhaler A (white actuator) for a 14-day treatment period. They were instructed to take two puffs twice daily (morning and evening), for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. The medication was administered as a metered-dose inhalation of a pressurized solution using a standard actuator. After completing the first treatment period, participants switched to Inhaler B (pink actuator) for another 14 days. The dosage and administration remained identical to the first phase: two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate + 12 µg Formoterol fumarate. There was no washout period between treatments, as the crossover design allowed a direct switch from one inhaler to the other without interruption.
Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A) · Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)
Participants in this group first received Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg pressurized metered-dose inhaler (CHF1535 100/6 µg pMDI) using Inhaler B (pink actuator) for a 14-day treatment period. They were instructed to take two puffs twice daily (morning and evening), for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. The medication was administered as a metered-dose inhalation of a pressurized solution using a standard actuator. After completing the first treatment period, participants switched to Inhaler A (white actuator) for another 14-day treatment period. The dosage and administration remained identical to the first phase: two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate + 12 µg Formoterol fumarate. There was no washout period between treatments, as the crossover design allowed a direct switch from one inhaler to the other without interruption.
Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A) · Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)
Drug page: Beclomethasone
Administered via Inhaler A (white actuator) as two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. Delivered as a pressurized metered-dose inhalation (pMDI) in a randomized, double-blind, crossover study.
Also known as: CHF1535 100/6 µg pMDI
Drug page: Beclomethasone
Administered via Inhaler B (pink actuator) as two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. Delivered as a pressurized metered-dose inhalation (pMDI) in a randomized, double-blind, crossover study.
Also known as: CHF1535 100/6 µg pMDI
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3
A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), with subjects rating their asthma symptoms from the previous day on a VAS scale from 0=no symptoms to 100=very symptomatic, with lower scores corresponding to better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported.
Time frame: Baseline and Treatment Day 14 within each treatment period
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #4
A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #4 (How burdensome was your asthma yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), requiring subjects to rate the burden of their asthma symptoms from the previous day on a VAS scale ranging from 0 to 100, where 0=no burden at all and 100=very burdensome. Lower scores corresponded to better health and lower perceived burden of asthma. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means by treatment are reported with their relative 95% IC.
Time frame: Baseline and Treatment Day 14 within each treatment period
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #5
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no improvement; 100 = maximum improvement), where higher scores indicated better health.The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their 95% IC.
Time frame: Baseline and Treatment Day 14 within each treatment period
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #6
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #6 ("Did your asthma symptoms worsen yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no worsening; 100 = maximum worsening), where lower scores indicated better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their relative 95% IC.
Time frame: Baseline and Treatment Day 14 within each treatment period
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #3
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptoms were assessed using a VAS, ranging from 0=no symptoms to 100=very severe symptoms. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43). First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. Change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means reported with their 95%IC.
Time frame: Baseline and Treatment Day 7 within each treatment period
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #4
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma burden was assessed using a Visual Analogue Scale (VAS) ranging from 0=no burden to 100=very burdensome condition. Lower scores corresponded to better health. Question #4 (How burdensome was your asthma yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period = average of the VAS scores collected over the first week of treatment within each period. Here the change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment.
Time frame: Baseline and Treatment Day 7 within each treatment period
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #5
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100, where 0 indicated no improvement at all and 100 indicated maximum improvement. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score. Adjusted means are reported with their 95%IC
Time frame: Baseline and Treatment Day 7 within each treatment period
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #6
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom worsening was assessed using a VAS, ranging from 0=no worsening at all to 100= maximum worsening. Question #6 (Did your asthma symptoms worsen yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means are reported.
Time frame: Baseline and Treatment Day 7 within each treatment period
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #7
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #7 (Do you expect any improvement in asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=no expected improvement to 100=maximum expected improvement. Higher scores corresponded to greater expectations of benefit.Summary measures for this question were presented separately as descriptive statistics for the ITT population.
Time frame: Baseline - V2 (Day 15)
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #8
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #8 (Do you expect any worsening of your asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=none to 100=maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.
Time frame: Baseline - V2 (Day 15)
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #9
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #9 ("How much do you think this treatment improved your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived improvement in overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum improvement. Higher scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.
Time frame: Study Day 14 of each treatment period
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #10
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #10 ("How much do you think this treatment worsened your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived worsening of overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.
Time frame: Study Day 14 of each treatment period (V3 - Day 29 for Period 1 and V4 - Day 43 Period 2)
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #11
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions was completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' visual preference for the inhalers was assessed through Question #11 ("Which inhaler did you visually prefer?"). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.
Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #12
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' preference for inhaler use was assessed through Question #12 ("Which inhaler did you prefer to use?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.
Time frame: Day 43 (V4, i.e.at the end of the entire treatment period during the Exit Interview)
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #13
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of changes in the inhalers was assessed through Question #13 ("Do you think that changes were made to the inhalers?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.
Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #14
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of the impact of inhaler changes on asthma symptoms was assessed through Question #14 ("Do you think that changes made across the inhalers have impacted your asthma symptoms?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.
Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #15
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of asthma symptoms after receiving information about the inhalers was assessed through Question #15 ("Based on the information you have received, did it impact your perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.
Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #16
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of which inhaler had the biggest impact on their asthma symptoms was assessed through Question #16 ("Which of Inhaler A or Inhaler B had the biggest impact on the perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or I don't know. The number and % of subjects selecting one of the 3 options was reported separately by treatment group.
Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Change From Baseline in Average Reliever Medication Use - Over the Entire 14-day Treatment - Question #2
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while others were answered at specific study visit timepoints. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Rescue medication use was assessed through Question #2 (How many puffs of rescue medication have you taken yesterday?), answered daily every morning throughout the entire 14-day treatment period, from the day after V1 (Day 2) to the end of the study at V4 (Day 43). The average number of puffs per day was calculated for both the baseline and treatment periods, and the change from baseline was summarized separately for the ITT population by treatment group. Average value for each treatment period = mean number of puffs per day collected over Study Day 1 to Study Day 14 of each treatment period.
Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 for Period 2)
Change From Baseline in AQLQ Activity Limitation Score - After 14 Days of Treatment
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day15) and V3 (Day29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Change From Baseline in AQLQ Symptoms Score - After 14 Days of Treatment
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Change From Baseline in AQLQ Emotional Function Score - After 14 Days of Treatment
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Change From Baseline in AQLQ Environmental Stimuli Score - After 14 Days of Treatment
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Change From Baseline in AQLQ Overall Score - After 14 Days of Treatment
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). Overall score = Σ scores of each 32 domains/ no. of available items in overall AQLQ (0-1)
Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Occurrence of Treatment Emergent Adverse Event (TEAEs), Adverse Drug Reactions (ADRs), Severe ADRs, Serious ADRs, Serious TEAEs (Serious Adverse Events), Non-serious TEAEs, Severe TEAEs
An adverse event (AE) was defined as "any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment". An AE could therefore be any unfavourable and unintended sign (including abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An adverse drug reaction (ADR) was defined as an "untoward and unintended response to an investigational medicinal product related to any dose administered". A serious adverse event (SAE)/serious ADR was defined as any untoward medical occurrence or effect that at any dose: Resulted in death; Was life-threatening; Required hospitalisation or prolongation of existing hospitalisation; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was a medically significant AE.
Time frame: From V1 (Day 1) to V4 (Day 43)
A total of 81 patients were screened. 78 patients were randomized into two treatment sequences: * 39 received Inhaler A first, then Inhaler B. * 39 received Inhaler B first, then Inhaler A.
| Milestone | Sequence: Inhaler A - Inhaler B | Sequence: Inhaler B - Inhaler A |
|---|---|---|
| Started | 39 | 39 |
| Intention-to treat population (itt) | 36 | 38 |
| Per protocol population (pp) | 36 | 36 |
| Safety population (saf) | 36 | 38 |
| Completed | 36 | 36 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Other reason | 1 | 2 |
A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), with subjects rating their asthma symptoms from the previous day on a VAS scale from 0=no symptoms to 100=very symptomatic, with lower scores corresponding to better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3 | 2.68 (0.99 to 4.37) | 1.63 (-0.06 to 3.32) |
A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #4 (How burdensome was your asthma yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), requiring subjects to rate the burden of their asthma symptoms from the previous day on a VAS scale ranging from 0 to 100, where 0=no burden at all and 100=very burdensome. Lower scores corresponded to better health and lower perceived burden of asthma. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means by treatment are reported with their relative 95% IC.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #4 | 2.62 (0.58 to 4.65) | 1.82 (-0.22 to 3.85) |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no improvement; 100 = maximum improvement), where higher scores indicated better health.The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their 95% IC.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #5 | 0.25 (-1.27 to 1.76) | 1.54 (0.02 to 3.05) |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #6 ("Did your asthma symptoms worsen yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no worsening; 100 = maximum worsening), where lower scores indicated better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their relative 95% IC.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #6 | 2.53 (0.82 to 4.25) | 1.66 (-0.05 to 3.38) |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptoms were assessed using a VAS, ranging from 0=no symptoms to 100=very severe symptoms. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43). First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. Change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means reported with their 95%IC.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #3 | 2.91 (1.40 to 4.42) | 1.72 (0.22 to 3.22) |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma burden was assessed using a Visual Analogue Scale (VAS) ranging from 0=no burden to 100=very burdensome condition. Lower scores corresponded to better health. Question #4 (How burdensome was your asthma yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period = average of the VAS scores collected over the first week of treatment within each period. Here the change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #4 | 2.82 (0.88 to 4.77) | 1.78 (-0.15 to 3.71) |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100, where 0 indicated no improvement at all and 100 indicated maximum improvement. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score. Adjusted means are reported with their 95%IC
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #5 | 0.69 (-1.64 to 3.02) | 1.45 (-0.86 to 3.76) |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom worsening was assessed using a VAS, ranging from 0=no worsening at all to 100= maximum worsening. Question #6 (Did your asthma symptoms worsen yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means are reported.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #6 | 2.08 (0.15 to 4.00) | 1.94 (0.02 to 3.85) |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #7 (Do you expect any improvement in asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=no expected improvement to 100=maximum expected improvement. Higher scores corresponded to greater expectations of benefit.Summary measures for this question were presented separately as descriptive statistics for the ITT population.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #7 | 64.5 ± 34.3 | 60.8 ± 36.8 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #8 (Do you expect any worsening of your asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=none to 100=maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #8 | 8.9 ± 17.0 | 8.0 ± 16.2 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #9 ("How much do you think this treatment improved your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived improvement in overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum improvement. Higher scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #9 | 41.1 ± 36.5 | 44.6 ± 35.8 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #10 ("How much do you think this treatment worsened your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived worsening of overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #10 | 8.0 ± 14.9 | 11.8 ± 17.2 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions was completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' visual preference for the inhalers was assessed through Question #11 ("Which inhaler did you visually prefer?"). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.
| Participants | Overall |
|---|---|
| Inhaler A | 14 |
| Inhaler B | 17 |
| No preference | 27 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' preference for inhaler use was assessed through Question #12 ("Which inhaler did you prefer to use?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.
| Participants | Overall |
|---|---|
| Inhaler A | 20 |
| Inhaler B | 16 |
| No Preference | 22 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of changes in the inhalers was assessed through Question #13 ("Do you think that changes were made to the inhalers?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.
| Participants | Overall |
|---|---|
| Yes | 27 |
| No | 17 |
| I do not know | 14 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of the impact of inhaler changes on asthma symptoms was assessed through Question #14 ("Do you think that changes made across the inhalers have impacted your asthma symptoms?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.
| Participants | Overall |
|---|---|
| Yes | 14 |
| No | 10 |
| I do not know | 3 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of asthma symptoms after receiving information about the inhalers was assessed through Question #15 ("Based on the information you have received, did it impact your perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.
| Participants | Overall |
|---|---|
| Yes | 12 |
| No | 39 |
| I do not Know | 7 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of which inhaler had the biggest impact on their asthma symptoms was assessed through Question #16 ("Which of Inhaler A or Inhaler B had the biggest impact on the perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or I don't know. The number and % of subjects selecting one of the 3 options was reported separately by treatment group.
| Participants | Overall |
|---|---|
| Inhaler A | 18 |
| Inhaler B | 13 |
| No preference | 27 |
A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while others were answered at specific study visit timepoints. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Rescue medication use was assessed through Question #2 (How many puffs of rescue medication have you taken yesterday?), answered daily every morning throughout the entire 14-day treatment period, from the day after V1 (Day 2) to the end of the study at V4 (Day 43). The average number of puffs per day was calculated for both the baseline and treatment periods, and the change from baseline was summarized separately for the ITT population by treatment group. Average value for each treatment period = mean number of puffs per day collected over Study Day 1 to Study Day 14 of each treatment period.
| puffs/day | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in Average Reliever Medication Use - Over the Entire 14-day Treatment - Question #2 | -0.06 ± 0.69 | -0.04 ± 0.74 |
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day15) and V3 (Day29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in AQLQ Activity Limitation Score - After 14 Days of Treatment | 0.10 ± 0.41 | 0.04 ± 0.53 |
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in AQLQ Symptoms Score - After 14 Days of Treatment | -0.03 ± 0.42 | 0.00 ± 0.66 |
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in AQLQ Emotional Function Score - After 14 Days of Treatment | 0.06 ± 0.37 | 0.04 ± 0.71 |
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in AQLQ Environmental Stimuli Score - After 14 Days of Treatment | 0.11 ± 0.70 | 0.13 ± 0.61 |
Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). Overall score = Σ scores of each 32 domains/ no. of available items in overall AQLQ (0-1)
| score on a scale | Inhaler A | Inhaler B |
|---|---|---|
| Change From Baseline in AQLQ Overall Score - After 14 Days of Treatment | 0.05 ± 0.37 | 0.04 ± 0.53 |
An adverse event (AE) was defined as "any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment". An AE could therefore be any unfavourable and unintended sign (including abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An adverse drug reaction (ADR) was defined as an "untoward and unintended response to an investigational medicinal product related to any dose administered". A serious adverse event (SAE)/serious ADR was defined as any untoward medical occurrence or effect that at any dose: Resulted in death; Was life-threatening; Required hospitalisation or prolongation of existing hospitalisation; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was a medically significant AE.
| Participants | Inhaler A - SAF Population | Inhaler B - SAF Population | Overall |
|---|---|---|---|
| TEAE | 7 | 6 | 11 |
| Serious TEAE | 0 | 0 | 0 |
| Non-serious TEAE | 7 | 6 | 11 |
| ADR | 1 | 2 | 3 |
| Serious ADR | 0 | 0 | 0 |
| Severe ADR | 0 | 0 | 0 |
| Severe TEAE | 0 | 0 | 0 |
| TEAE leading to discontinuation of study treatment | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 |
Collected over Throughout the study, from Visit 1 (Day 1 - study screening and along the baseline period [Day 1- Day 14]) until Visit 4 (Day 43 ± 1 day, i.e. the end of the second treatment period).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaler A - SAF Population | 0/72 (0%) | 0/72 (0%) | 7/72 (9.7%) |
| Inhaler B - SAF Population | 0/74 (0%) | 0/74 (0%) | 6/74 (8.1%) |
| Overall | 0/74 (0%) | 0/74 (0%) | 11/74 (14.9%) |
| Event | Inhaler A - SAF Population | Inhaler B - SAF Population | Overall |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/72 | 4/74 | 4/74 |
| COVID-19Infections and infestations | 2/72 | 1/74 | 3/74 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/72 | 2/74 | 2/74 |
| Oral discomfortGastrointestinal disorders | 1/72 | 0/74 | 1/74 |
| InfluenzaInfections and infestations | 1/72 | 0/74 | 1/74 |
| NasopharyngitisInfections and infestations | 1/72 | 0/74 | 1/74 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/72 | 0/74 | 1/74 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 1/72 | 0/74 | 1/74 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/72 | 0/74 | 1/74 |
| HypertensionVascular disorders | 1/72 | 0/74 | 1/74 |
Intention-to-treat (ITT) set: all randomised subjects who received at least one dose of the study treatment and with at least one available evaluation of efficacy after the baseline. Using this definition, subjects with data just in one treatment period were not taken into account by the statistical models for the calculation of the treatment difference. The ITT set analyses were based on the randomised treatment for each period.
| Age, Continuous(years) | Sequence Inhaler A → Inhaler B (ITT Population) - Period 1 | Sequence Inhaler B → Inhaler A (ITT Population) - Period 2 | Total |
|---|---|---|---|
| Mean | 47 ± 16.2 | 51.6 ± 15.2 | 49.4 ± 15.7 |
| Sex: Female, Male(Participants) | Sequence Inhaler A → Inhaler B (ITT Population) - Period 1 | Sequence Inhaler B → Inhaler A (ITT Population) - Period 2 | Total |
|---|---|---|---|
| Female | 21 | 19 | 40 |
| Male | 15 | 19 | 34 |
| Race/Ethnicity, Customized(Participants) | Sequence Inhaler A → Inhaler B (ITT Population) - Period 1 | Sequence Inhaler B → Inhaler A (ITT Population) - Period 2 | Total |
|---|---|---|---|
| White | 36 | 38 | 74 |
| Asian | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sequence Inhaler A → Inhaler B (ITT Population) - Period 1 | Sequence Inhaler B → Inhaler A (ITT Population) - Period 2 | Total |
|---|---|---|---|
| Italy | 36 | 38 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Feb 2023, 11 months.
Results were first posted in Mar 2026, 3 years 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 11 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone